leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Product code: PHA0265

  • Publication date: 05/12/2017
  • Number of Pages: 171
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

The Global Chronic Kidney Disease (CKD) Drugs market reached $12.2bn in 2016 and is expected to grow at a CAGR of 3.9% in the first half of the forecast period. The market is dominated by calcium channel blockers and ACE inhibitors.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 171-page report you will receive 85 tables and 93 figures – all unavailable elsewhere.

The 171-page report provides clear detailed insight into the Global Chronic Kidney Disease (CKD) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Chronic Kidney Disease (CKD) Drugs market forecasts from 2018-2028

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by drug class:
- ACE inhibitors
- Angiotensin-II receptor blockers
- Calcium channel blockers
- Beta blockers: BREVIBLOC, Bystolic
- Erythropoiesis-stimulating agents (ESAs)
- Diuretics
- Others

This report provides a SWOT Analysis for each drug class.

• This report provides revenue forecast for these leading drugs:
- Aceon
- Lisinopril
- Losartan
- AVAPRO
- Twynsta
- BREVIBLOC
- Bystolic
- Mircera
- Epoetin Alfa BS
- Natrilix SR
- Spironolactone
- Urief
- AURYXIA

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by distribution channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others

• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by regional and national market:
- North America: US and Canada
- Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
- Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
- Latin America: Brazil, Mexico, Rest of Latin America
- Middle East & Africa: Saudi Arabia, South of Africa, Rest of MEA

Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

Each regional market is further broken down by drug class and distribution channel.

• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the Global Chronic Kidney Disease (CKD) Drugs market:
- Pfizer, Inc.
- Amgen
- Roche
- GlaxoSmithKline (GSK)
- Allergan
- AbbVie
- Kissei Pharmaceutical Co., Ltd.

Buy our report today Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 Global Chronic Kidney Disease Drugs Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Chronic Kidney Disease Drugs Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Introduction to Chronic Kidney Disease Drugs
2.1 An Introduction to Chronic Kidney Disease Drugs
2.2. ACE Inhibitors
2.3. Angiotensin-II Receptor Blockers
2.4. Calcium Channel Blockers
2.5. Beta Blockers
2.6. Erythropoiesis-stimulating agents (ESAs)
2.7. Diuretics
2.8. Drivers
2.8.1. High Prevalence of Chronic Kidney Disease (CKD) Worldwide
2.8.2. Rise in Incidence of Cardiovascular Disorders and Diabetes
2.9. Restraints
2.9.1 Competition from Biosimilars Due to Patent Loss

3. Global Chronic Kidney Disease Drugs Market by Product Type 2018-2028
3.1 Global Chronic Kidney Disease Drugs Market Forecast 2018-2028
3.2 Changing Market Shares by Drug Class 2018-2028
3.3. Global ACE Inhibitors Market: Sales Forecast 2018-2028
3.3.1. Aceon (Abbott Laboratories)
3.3.2. Lisinopril (GlaxoSmithKline plc.)
3.3.3. SWOT Analysis of the ACE Inhibitors Market, 2018-2028
3.3.3.1. Strength
3.3.3.1.1. Advantages of ACE Inhibitors drugs
3.3.3.2. Weakness
3.3.3.2.1. Side effect of ACE Inhibitors
3.3.3.3. Opportunity
3.3.3.3.1. Increasing prevalence of cardiovascular disease
3.3.3.4. Threat
3.3.3.4.1. Competitive and Fragmented market
3.4. Global Angiotensin-II Receptor Blockers Market: Sales Forecast 2018-2028
3.4.1. Losartan (Morepen Laboratories Ltd.)
3.4.2. AVAPRO (Sanofi S.A.)
3.4.3. SWOT Analysis of the Angiotensin-II Receptor Blockers Market, 2018-2028
3.4.3.1. Strength
3.4.3.1.1. Blood pressure lowering efficacy in patients with hypertension
3.4.3.2. Weakness
3.3.3.2.1. Side effects during pregnancy
3.4.3.3. Opportunity
3.4.3.3.1. Increasing prevalence of Diabetic Kidney Disease
3.4.3.4. Threat
3.4.3.4.1. Fewer interactions with other drugs
3.5 Global Calcium Channel Blockers Market: Sales Forecast 2018-2028
3.5.1. Norvasc (Pfizer Inc.)
3.5.2. Twynsta (Boehringer Ingelheim Pharmaceuticals, Inc.)
3.5.3. SWOT Analysis of the Calcium Channel Blockers Market, 2018-2028
3.5.3.1. Strength
3.5.3.1.1. Favourable Reimbursement Scenario
3.5.3.2. Weakness
3.5.3.2.1. Side effect of Calcium Channel Blockers
3.5.3.3. Opportunity
3.5.3.3.1. Rising prevalence of hypertension across the globe
3.5.3.4. Threat
3.5.3.4.1. Availability of cost effective biosimilars
3.6. Global Beta Blockers Market: Sales Forecast 2018-2028
3.6.1. BREVIBLOC (Baxter International Inc.)
3.6.2. Bystolic (ALLERGAN)
3.6.3. SWOT Analysis of the Beta Blockers Market, 2018-2028
3.6.3.1. Strength
3.6.3.1.1. Advantages of Beta Blockers
3.6.3.2. Weakness
3.6.3.2.1. Can’t be used by Diabetes Patients
3.6.3.3. Opportunity
3.6.3.3.1. Increasing prevalence of heart failure
3.6.3.4. Threat
3.6.3.4.1. Availability of cost effective biosimilars
3.7. Global Erythropoiesis-stimulating agents (ESAs) Market: Sales Forecast 2018-2028
3.7.1. Mircera (F. Hoffmann-La Roche AG)
3.7.2. Epoetin Alfa BS (Japan Chemical Research Pharmaceuticals Co., Ltd.)
3.7.3. SWOT Analysis of the Erythropoiesis-stimulating agents (ESAs) Market, 2018-2028
3.7.3.1. Strength
3.7.3.1.1. Mircera launched in the U.S.
3.7.3.2. Weakness
3.7.3.2.1. Mircera is not a preferred brand of the Payers
3.7.3.3. Opportunity
3.7.3.3.1. Increased incidences of kidney failures
3.7.3.4. Threat
3.7.3.4.1. Availability of cost effective biosimilars
3.8. Global Diuretics Market: Sales Forecast 2018-2028
3.8.1. Natrilix SR (Serdia Pharmaceuticals Pvt. Ltd.)
3.8.2. Spironolactone (Pfizer, Inc.)
3.8.3. SWOT Analysis of the Diuretics Market, 2018-2028
3.8.3.1. Strength
3.8.3.1.1. Reduces Risk of Congestive heart Failure Hospitalization
3.8.3.2. Weakness
3.8.3.2.1. Can Cause Heart Rhythm Problems
3.8.3.3. Opportunity
3.8.3.3.1. Increasing prevalence of Congestive Heart Failure
3.8.3.4. Threat
3.8.3.4.1. Generic Competition
3.9. Global Others Market: Sales Forecast 2018-2028
3.9.1. Urief (Kissei Pharmaceutical Co., Ltd., Eisai Co., Ltd)
3.9.2. AURYXIA (Keryx Biopharmaceuticals, Inc.)

4. Global Chronic Kidney Disease Drugs Market by Distribution Channel 2018-2028
4.1 Global Chronic Kidney Disease Drugs Market Forecast by Distribution Channel 2018-2028
4.1.1. Hospital Pharmacies
4.1.2. Retail Pharmacies
4.1.3. Online Pharmacies
4.1.4. Others (Clinics, Supermarket Drug Stores, etc.)

5. Leading National Markets 2018-2028
5.1. Geographical Breakdown of the World Chronic Kidney Disease Drugs Market
5.2 Chronic Kidney Disease Drugs Market: Regional Market Forecast 2018-2028
5.2.1 How Will Regional Market Shares Change to 2028?

6. North America Chronic Kidney Disease Drugs Market 2018-2028
6.1. U.S. Chronic Kidney Disease Drugs Market: Trends and Developments
6.2. Canada Chronic Kidney Disease Drugs Market: Trends and Developments

7. Europe Chronic Kidney Disease Drugs Market 2018-2028
7.1. Germany Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.2. France Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.3. U.K. Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.4. Italy Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.5. Spain Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.6. Rest of Europe Chronic Kidney Disease Drugs Market Forecast 2018-2028
8. Asia-Pacific Chronic Kidney Disease Drugs Market 2018-2028
8.1. China Chronic Kidney Disease Drugs Market: Trends and Developments
8.2. Japan Chronic Kidney Disease Drugs Market: Trends and Developments
8.3. India Chronic Kidney Disease Drugs Market: Trends and Developments
8.4. Rest of Asia-Pacific Chronic Kidney Disease Drugs Market: Trends and Developments

9. Latin America Chronic Kidney Disease Drugs Market 2018-2028
9.1 Brazil Chronic Kidney Disease Drugs Market: Trends and Developments
9.2. Mexico Chronic Kidney Disease Drugs Market: Trends and Developments
9.3. Rest of Latin America Chronic Kidney Disease Drugs Market: Trends and Developments

10. Middle East & Africa Chronic Kidney Disease Drugs Market 2018-2028
10.1. Saudi Arabia Chronic Kidney Disease Drugs Market Forecast 2018-2028
10.2. South Africa Chronic Kidney Disease Drugs Market Forecast 2018-2028
10.3. Rest of Middle East & Africa Chronic Kidney Disease Drugs Market Forecast 2018-2028

11. Leading Companies in the Chronic Kidney Disease Drugs
11.1. Sanofi S.A.
11.1.1 Sanofi S.A.: Chronic Kidney Disease Drugs Portfolio
11.1.2 Sanofi S.A.: Financial Overview
11.1.3 Sanofi S.A.: Recent Developments
11.2. Pfizer, Inc.
11.2.1 Pfizer, Inc.: Chronic Kidney Disease Drugs Portfolio
11.2.2 Pfizer, Inc.: Financial Overview
11.2.3 Pfizer, Inc.: Recent Developments
11.3. Amgen, Inc.
11.3.1 Amgen, Inc.: Chronic Kidney Disease Drugs Portfolio
11.3.2 Financial Overview
11.3.3. Recent Transactions Summary
11.4. F. Hoffmann-La Roche AG
11.4.1 Roche: Chronic Kidney Disease Drugs Portfolio
11.4.2 Roche: Financial Overview
11.4.3. Recent Transactions Summary
11.5. GlaxoSmithKline plc
11.5.1 GlaxoSmithKline plc: Chronic Kidney Disease Drugs Portfolio
11.5.2 GlaxoSmithKline plc: Financial Overview
11.5.3 GlaxoSmithKline plc: Recent Transactions Summary
11.6. Allergan plc
11.6.1 Allergan plc: Chronic Kidney Disease Drugs Portfolio
11.6.2 Allergan plc: Financial Overview
11.6.3 Allergan plc: Recent Transactions Summary
11.7. AbbVie Inc.
11.7.1 AbbVie Inc.: Chronic Kidney Disease Drugs Portfolio
11.7.2 AbbVie Inc.: Financial Overview
11.7.3 AbbVie Inc.: Recent Transactions Summary
11.8. Kissei Pharmaceutical Co., Ltd
11.8.1 Kissei Pharmaceutical Co., Ltd.: Chronic Kidney Disease Drugs Portfolio
11.8.2 Kissei Pharmaceutical Co., Ltd.: Financial Overview
11.8.3 Kissei Pharmaceutical Co., Ltd.: Recent Transactions Summary

12. Conclusions
12.1 The World Chronic Kidney Disease Drugs Market in 2016 and 2017
12.1.1 Current Leading Chronic Kidney Disease Drugs Segments
12.1.2 Leading Regional Markets
12.2 World Chronic Kidney Disease Drugs Market Forecast 2017-2027
12.3 The Future of the Military Medical & Humanitarian Trauma Care Market?

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 3.1 Global Chronic Kidney Disease Drugs Market by Drugs Class: Revenue ($m) and Market Share (%), 2016
Table 3.2 Global Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.3 Global ACE Inhibitors Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.4 Global Aceon Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.5 Global Lisinopril Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.6 SWOT Analysis of the ACE Inhibitors Market, 2018-2028
Table 3.7 Global Angiotensin-II Receptor Blockers Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.8 Global Losartan Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.9 Global AVAPRO Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.10 SWOT Analysis of the Angiotensin-II Receptor Blockers Market, 2018-2028
Table 3.11 Global Calcium Channel Blockers Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.12 Global Norvasc Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.13 Global Twynsta Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.14 SWOT Analysis of the Calcium Channel Blockers Market, 2018-2028
Table 3.15 Global Beta Blockers Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.16 Global BREVIBLOC Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.17 Global Bystolic Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.18 SWOT Analysis of the Beta Blockers Market, 2018-2028
Table 3.19 Global Erythropoiesis-stimulating agents (ESAs) Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.20 Global Mircera Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.21 Global Epoetin Alfa BS Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.22 SWOT Analysis of the Erythropoiesis-stimulating agents (ESAs) Market, 2018-2028
Table 3.23 Global Diuretics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.24 Global Natrilix SR Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.25 Global Spironolactone Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.26 SWOT Analysis of the Diuretics Market, 2018-2028
Table 3.27 Global Others Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.28 Global Urief Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.29 Global AURYXIA Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.1 Global Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.2 Global Hospital Pharmacies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.3 Global Retail Pharmacies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.4 Global Online Pharmacies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.5 Global Others Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 5.1 Global Chronic Kidney Disease Drugs Market by Region: Revenue ($m), 2016 and 2017
Table 5.2 Global Chronic Kidney Disease Drugs Market Forecast, by Region: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.1 North America Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.2 North America Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.3 North America Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.4 U.S. Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.5 Canada Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.1 Europe Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.2 Europe Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.3 Europe Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.4 Germany Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.5 France Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.6 U.K. Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.7 Italy Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.8 Spain Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.9 Rest of Europe Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.1 Asia-Pacific Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 8.2 Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 8.3 Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, By Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 8.4 China Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.5 Japan Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.6 India Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.7 Rest of Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 9.1 Latin America Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 9.2 Latin America Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 9.3 Latin America Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 9.4 Brazil Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 9.5 Mexico Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 9.6 Rest of Latin America Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 10.1 Middle East & Africa Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.2 Middle East & Africa Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.3 Middle East & Africa (MEA) Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.4 Saudi Arabia Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.5 South Africa Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 10.6 Rest of MEA Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 11.1 Sanofi S.A.: Overview, 2017
Table 11.2 Sanofi S.A.: Revenue ($m), AGR (%), 2012-2016
Table 11.3 Pfizer, Inc.: Overview, 2017
Table 11.4 Pfizer, Inc.: Revenue ($m), AGR (%), 2012-2016
Table 11.5 Amgen, Inc. Corporation: Overview, 2017
Table 11.6 Amgen, Inc.: Revenue ($m), AGR (%), 2012-2016
Table 11.7 Roche: Overview, 2017
Table 11.8 Roche: Revenue ($m), AGR (%), 2012-2016
Table 11.9 GlaxoSmithKline plc: Overview, 2017
Table 11.10 GlaxoSmithKline plc: Revenue ($m), AGR (%), 2012-2016
Table 11.11 Allergan plc: Overview, 2017
Table 11.12 Allergan plc: Revenue ($m), AGR (%), 2012-2016
Table 11.13 AbbVie Inc.: Overview, 2017
Table 11.14 AbbVie Inc.: Revenue ($m), AGR (%), 2012-2016
Table 11.15 Kissei Pharmaceutical Co., Ltd: Overview, 2017
Table 11.16 Kissei Pharmaceutical Co., Ltd: Revenue ($m), AGR (%), 2013-2017

List of Figure
Figure 1.1 Global Chronic kidney diseases Drugs Market Segmentation Overview
Figure 3.1 Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share (%), 2016
Figure 3.2 Global Chronic Kidney Disease Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.3 Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share (%), 2016
Figure 3.4 Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share (%), 2022
Figure 3.5 Global Chronic Kidney Disease Drugs Market by Drugs Class: Market Share (%), 2028
Figure 3.6 Global ACE Inhibitors Segment Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.7 Global Aceon Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.8 Global Lisinopril Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.9 Global Angiotensin-II Receptor Blockers Segment Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.10 Global Losartan Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.11 Global AVAPRO Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.12 Global Calcium Channel Blockers Segment Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.13 Global Norvasc Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.14 Global Twynsta Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.15 Global Beta Blockers Segment Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.16 Global BREVIBLOC Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.17 Global Bystolic Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.18 Global Erythropoiesis-stimulating agents (ESAs) Segment Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.19 Global Mircera Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.20 Global Epoetin Alfa BS Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.21 Global Diuretics Segment Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.22 Global Natrilix SR Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.23 Global Spironolactone Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.24 Global Others Segment Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.25 Global Urief Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 3.26 Global AURYXIA Market Forecast: Revenue ($m), AGR (%), 2016-2028
Figure 4.1 Global Chronic kidney disease Drugs Market by Distribution Channel: Market Share (%), 2016
Figure 4.2 Global Hospital Pharmacies Segment Forecast: Revenue ($m), AGR (%), 2018-2028
Figure 4.3 Global Retail Pharmacies Segment Forecast: Revenue ($m), AGR (%), 2018-2028
Figure 4.4 Global Online Pharmacies Segment Forecast: Revenue ($m), AGR (%), 2018-2028
Figure 4.5 Global Others Segment Forecast: Revenue ($m), AGR (%), 2018-2028
Figure 5.1 Global Chronic Kidney Disease Drugs Market: Revenues ($m) by Region, 2016
Figure 5.2 Global Chronic Kidney Disease Drugs Market: Revenues ($m) by Region, 2017
Figure 5.3 Global Chronic Kidney Disease Drugs Market Forecast by Regional Market: Revenue ($m), 2016-2028
Figure 5.4 Global Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2016
Figure 5.5 Global Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2022
Figure 5.6 Global Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2028
Figure 6.1 North America Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 6.2 North America Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2016
Figure 6.3 North America Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2022
Figure 6.4 North America Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2028
Figure 6.5 U.S. Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 6.6 Canada Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 7.1 Europe Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 7.2 Europe Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2016
Figure 7.3 Europe Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2022
Figure 7.4 Europe Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2028
Figure 7.5 Germany Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 7.6 France Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 7.7 U.K. Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 7.8 Italy Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 7.9 Spain Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 7.10 Rest of Europe Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 8.1 Asia-Pacific Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 8.2 Asia-Pacific Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2016
Figure 8.3 Asia-Pacific Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2022
Figure 8.4 Asia-Pacific Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2028
Figure 8.5 China Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 8.6 Japan Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 8.7 India Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 8.8 Rest of Asia-Pacific Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 9.1 Latin America Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 9.2 Latin America Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2016
Figure 9.3 Latin America Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2022
Figure 9.4 Latin America Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2028
Figure 9.5 Brazil Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 9.6 Mexico Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 9.7 Rest of Latin America Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 10.1 Middle East & Africa Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 10.2 Middle East & Africa Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2016
Figure 10.3 Middle East & Africa Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2022
Figure 10.4 Middle East & Africa Chronic Kidney Disease Drugs Market: Market Shares (%) by Regional Market, 2028
Figure 10.5 Saudi Arabia Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 10.6 South Africa Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 10.7 Rest of MEA Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), 2016-2028
Figure 11.1 Sanofi S.A.: Revenue ($m), AGR (%), 2012-2016
Figure 11.2 Sanofi S.A.: Revenue, by Region, Share (%), 2016
Figure 11.3 Pfizer, Inc.: Revenue ($m), AGR (%), 2012-2016
Figure 11.4 Pfizer, Inc.: National Revenue Share (%), 2016
Figure 11.5 Amgen, Inc.: Revenue ($m), AGR (%), 2012-2016
Figure 11.6 Roche: Revenue ($m), AGR (%), 2012-2016
Figure 11.7 Roche: Business Segment Revenue Share (%), 2016
Figure 11.8 GlaxoSmithKline plc: Revenue ($m), AGR (%), 2012-2016
Figure 11.9 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2016
Figure 11.10 Allergan plc: Revenue ($m), AGR (%), 2012-2016
Figure 11.11 Allergan plc: Business Segment Revenue Share (%), 2016
Figure 11.12 AbbVie Inc.: Revenue ($m), AGR (%), 2012-2016
Figure 11.13 AbbVie Inc.: Geography Revenue Share (%), 2016
Figure 11.14 Kissei Pharmaceutical Co., Ltd: Revenue ($m), AGR (%), 2013-2017
Figure 11.15 Kissei Pharmaceutical Co., Ltd.: Business Segment Revenue Share (%), 2016
Figure 12.1 Global Chronic Kidney Disease Drugs Market by Product Type: Market Share (%), 2016
Figure 12.2 Chronic Kidney Disease Drugs Market, by Region Share (%), 2016, 2022, 2028

Companies Listed

Abbott Laboratories
AbbVie, Inc.
Allergan plc
Amgen, Inc.
AstraZeneca Pharmaceuticals LP
Bausch & Lomb Incorporated
Baxter International Inc.
Bayer
Boehringer Ingelheim GmbH
Eisai Co., Ltd
Emory Healthcare
F. Hoffmann-La Roche Ltd
Fresenius
Galenica
GlaxoSmithKline plc
Hospira
Instituto Terapeutico Delta Ltd
Japan Chemical Research Pharmaceuticals Co., Ltd.
Keryx Biopharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Lupin Laboratories Ltd.
Manus Aktteva Biopharma LLP.
Morepen Laboratories Ltd.
Novartis International AG
ObsEva
Pfizer, Inc.
Sanofi S.A.
Sanofi-aventis U.S. LLC
Serdia Pharmaceuticals Pvt. Ltd.
Teva Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals International, Inc.
Validus Pharmaceuticals, Inc.
Vifor Fresenius Medical Care Renal Pharma
Zydus Cadila

Other Organizations Mentioned in the Report
American Diabetes Association
American Kidney Fund
Asian Diabetes Prevention Initiative
Cancer Research U.K.
Centers for Disease Control and Prevention
Diabetes.co.uk
European Heart Network
Health Canada
Indian Heart Association
International Diabetes Federation
International Diabetes Foundation
National Center for Biotechnology Information
National Institute of Diabetes and Digestive and Kidney Diseases
National Kidney Foundation
National Organization of Rare Disorders
Servicio Sanitario Nazionale
Surgical Reconstruction and Microbiology Research Centre
The Kidney Foundation of Canada
U.S. Department of Commerce
U.S. Food and Drug Administration (FDA)
U.S. National Institutes of Health
United Nations
University of San Jose-Recoletos
World Economic Forum
World Health Organization

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close